Table 2.
Previous drug use in year before cohort entry in new users of statins. Figures are numbers (percentage) of patients
| Pravastatin (n=38 470) | Atorvastatin (n=268 254) | Fluvastatin/lovastatin (n=11 923) | Rosuvastatin (n=76 774) | Simvastatin (n=75 829 | |
|---|---|---|---|---|---|
| Steroids | 7054 (18.3) | 48 155 (18.0) | 1937 (16.2) | 14 065 (18.3) | 13 732 (18.1) |
| First generation antipsychotic | 274 (0.7) | 1415 (0.5) | 91 (0.8) | 310 (0.4) | 413 (0.5) |
| Second generation antipsychotic | 232 (0.6) | 3838 (1.4) | 39 (0.3) | 1237 (1.6) | 778 (1.0) |
| Immunosuppressants | 31 (0.1) | 127 (0.0) | 15 (0.1) | 15 (0.0) | 18 (0.0) |
| Protease inhibitors | 7 (0.0) | 28 (0.0) | 0 (0.0) | 16 (0.0) | ≤5 (0.0) |
| Lithium | 60 (0.2) | 578 (0.2) | 18 (0.2) | 146 (0.2) | 159 (0.2) |
| β blockers | 10 305 (26.8) | 70 555 (26.3) | 2824 (23.7) | 17 107 (22.3)* | 21 372 (28.2) |
| Thiazide diuretics | 5532 (14.4) | 51 141 (19.1)* | 1600 (13.4) | 15 755 (20.5)* | 12 697 (16.7) |
| Other diuretics | 3136 (8.2) | 22 780 (8.5) | 883 (7.4) | 5028 (6.5) | 6739 (8.9) |
| Niacin | ≤5 (0.0) | ≤5 (0.0) | 0 (0.0) | 31 (0.0) | ≤5 (0.0) |
| Phenytoin | 264 (0.7) | 1978 (0.7) | 67 (0.6) | 447 (0.6) | 539 (0.7) |
| Thyroid hormone | 4510 (11.7) | 33 410 (12.5) | 1432 (12.0) | 9672 (12.6) | 9073 (12.0) |
| Hormones and analogues | 3420 (8.9) | 20 947 (7.8) | 1130 (9.5) | 4408 (5.7)* | 6680 (8.8) |
| Isoniazid | ≤5 (0.0) | 19 (0.0) | ≤5 (0.0) | ≤5 (0.0) | 7 (0.0) |
| Nitroglycerin | 7063 (18.4) | 36 908 (13.8)* | 1739 (14.6)* | 5909 (7.7)* | 13 642 (18.0) |
| Angiotensin converting enzyme inhibitor | 10 331 (26.9) | 78 496 (29.3) | 2715 (22.8) | 21 397 (27.9) | 22 183 (29.3) |
| Angiotensin receptor blocker | 1526 (4.0) | 24 619 (9.2)* | 317 (2.7) | 13 363 (17.4)* | 4831 (6.4)* |
| Calcium channel blocker | 10 481 (27.2) | 68 389 (25.5) | 2782 (23.3) | 18 706 (24.4) | 20 164 (26.6) |
*Standardized mean difference >0.1.